Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

iPharma in-licenses Global Rights to FAK inhibitor from Boehringer Ingelheim

publication date: Nov 2, 2017

iPharma of Hong Kong in-licensed global rights from Boehringer Ingelheim to manufacture, develop, and commercialize BI 853520, a focal adhesion kinase inhibitor (FAKi) aimed at solid tumor cancers. iPharma is a joint venture between i-Bridge Capital, a China pharma investor, and BioLineRx, an Israeli biopharma. iPharma plans to start Phase I/II studies of BI 853520 in 2018 in combination with immune checkpoint inhibitors and/or potentially other therapies. iPharma will make an undisclosed upfront payment, plus pay milestones and royalties, though details were not disclosed. More details....

Stock Symbol: (NSDQ: BLRX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.